BRAIN Biotech is a key player in the bio-based economy
BRAIN Biotech AG ranks among the technologically leading companies in Europe in the bioeconomy area, and operates in industrial biotechnology with its key technologies.
BRAIN Biotech identifies previously untapped high-performing enzymes, microbial producer organisms and natural compounds derived from complex biological systems to transform them into industrially usable applications.
Innovative solutions and products developed from this Toolbox of Nature are successfully deployed in the chemicals sector, as well as in the cosmetics and food manufacturing industries.
As part of its growth-oriented industrialization strategy, BRAIN Biotech AG (ISIN DE0005203947 / WKN 520394) has been the first bioeconomy company to be listed in the Prime Standard of the Frankfurt Stock Exchange since February 2016.
Our products and solutions directly address the sustainability goals of the United Nations: 2, 3, 6, 9, and 12. Among other things, we aim to replace petrochemical processes by biotechnological processes, based on our proprietary resource collection, the BRAIN BioArchive.
Our innovative solutions (Tailor-made-solutions, TMS) as well as our products business show a low correlation with economic cycles and enable structural growth.
We have a broad and profound technological expertise in enzymes, microorganisms, cell-based testing methods and natural products. Combined with our collection of natural resources, the BRAIN BioArchive, we develop disruptive new biobased products and solutions.
Reliable
R&D partner
In more than 100 successfully completed R&D partnerships (Tailor made Solutions, TMS) we have proven our competence and reliability.
Our proprietary BRAIN BioArchive, an extensive patent portfolio, our broad and in-depth technology know-how as well as our first class scientists build high barriers to market entry.
We address important
We serve the concept 
Products for diverse
Broad and in-depth 
Reliable
Markets with high